New combo attack on liver tumors shows promise in early trial
NCT ID NCT03223779
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called TAS-102 (Lonsurf) combined with a precise type of radiation (SBRT) in 52 people whose colorectal cancer had spread to the liver. The goal was to find the safest dose and see if the combination could control the liver tumors. The trial is complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAS-102 (Lonsurf, trifluridine) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If this combination works well, it could offer a new way to control liver tumors in people with colorectal cancer that has spread.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 52 participants, so results are preliminary. The drug and radiation can cause side effects like low blood counts and liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02215, United States